Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CombiMucor combination therapy study in mucormycosis
2025-521505-40-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isavuconazole and amphotericin b in mucormycosis, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Favorable global response at week 4. Planned start Oct 2026; status: authorised.
02
Drugs
isavuconazoleamphotericin b
03
Conditions
mucormycosis
Beyond the preview
Go deeper on 2025-521505-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521505-40-00.